Clinical trials: Treatment Resistant Psychosis
Clozapine Resistant Schizophrenia
Vitamin D for Schizophrenia
Background: Despite improvements in medications, treatment delivery and rehabilitation, schizophrenia outcomes remain suboptimal. There are a proportion of 30-40% treatment-resistant schizophrenia patients.
- Trial name
- NCT01759485
- Testing
- Vitamin D3
- Where
- Israel
- Volunteers
- 47 people
- Sponsor
- Geha Mental Health Center
Diabetes, Schizophrenia
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
This is a study with an approved drug for treating type 2 diabetes, for its effects on treating glucose and lipid abnormalities in patients being treated with first or second-generation antipsychotics, and comparison of effects…
- Conditions
- Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
- Trial name
- NCT00231894
- Testing
- Pioglitazone, Life style diet group
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Refractory Schizophrenia
Deep Brain Stimulation of the Nucleus Accumbens and Anterior Limb of the Internal Capsule in the Treatment of Refractory Schizophrenia
Schizophrenia is a lifelong psychiatric disorder with a prevalence rate of 0.559% and a lifetime prevalence rate of 0.588% among Chinese adults.
- Trial name
- NCT07369401
- Testing
- Deep Brain Stimulation
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Schizophrenia
Augmenting Clozapine With Sertindole - SERCLOZ
The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00345982
- Testing
- Serdolect
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Treatment Resistant Schizophrenia
Comparison of Maintenance ECT Versus Clozapine in Treatment-resistant Schizophrenia
The proposed study will be conducted to compare the efficacy of maintenance ECT (M-ECT) vs Clozapine in treatment resistant schizophrenia (TRS) in terms of change in psychopathology measures and cerebral hemodynamics.
- Trial name
- NCT03807882
- Testing
- Bilateral M-ECT, Clozapine
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizoaffective Disorder
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of…
- Trial name
- HDQ (NCT00297947)
- Testing
- quetiapine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Schizotypal Disorder
Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis
The aim of the COPUS study is to investigate, whether it is possible to recruit and retain young people with first-episode psychosis, to an 8 week supervised High-Intensity Functional Training intervention (HIFT) (i.e.
- Conditions
- Schizophrenia, Schizotypal Disorder, First Episode Psychosis, Psychotic Disorders
- Trial name
- COPUS (NCT03409393)
- Testing
- The COPUS intervention, Usual Care (OPUS treatment)
- Where
- Denmark
- Volunteers
- 27 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Subjects Had Unipolar, Non-psychotic Major Depression
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
Atypical neuroleptics may have antidepressant qualities in bipolar depression and in unipolar depression. Some data support the use of both Risperidone and Olanzapine, but there are no direct comparisons of their relative…
- Trial name
- NCT01282632
- Testing
- Risperidone, Olanzapine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Sunnybrook Health Sciences Centre
Clozapine Resistant Schizophrenia
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS.
- Trial name
- NCT06501339
- Testing
- maintenance ECT, Aripiprazole tablet
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Affective Disorder, Schizoaffective Disorder
Specialized Clozapine Clinic for Bipolar and Schizoaffective Disorder
Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients. determine if after 12 months of treatment with clozapine, the BMI changes with clients who are councelled as usual regarding weight gain while on Clozapine.
- Trial name
- NCT00683709
- Testing
- Counselling as Usual, CBT
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Schizophrenia, Treatment Resistant Disorders
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general population. About 30% of patients will not react to current drug treatment and defined as treatment-resistant schizophrenia patients…
- Trial name
- ClozAmi (NCT01448499)
- Testing
- Clozapine, Amisulpride, Clozapine+Amisulpride
- Where
- Israel
- Sponsor
- Geha Mental Health Center
Schizophrenia, Auditory Hallucinations
Transcranial Direct Current Stimulation (tDCS) and Hallucinations in Schizophrenia
The purpose of this study is to determine whether trans Direct Current Stimulation (tDCS) is effective in the treatment of auditory hallucinations in schizophrenia.
- Trial name
- NCT00870909
- Testing
- active tDCS
- Where
- 2 sites in France, Tunisia
- Volunteers
- 46 people
- Sponsor
- Hôpital le Vinatier
Refractory Schizophrenia, Super Refractory Schizophrenia
Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia
Introduction: In spite of recent advances in schizophrenia treatment, 30% of patients still do not respond properly to antipsychotic therapy.
- Trial name
- SSURECT (NCT02049021)
- Testing
- MECTA SPECTRUM 5000Q ECT
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).
- Trial name
- NCT03652974
- Testing
- sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Treatment Resistant Depression (TRD)
Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to Treatment
The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments.
- Conditions
- Schizophrenia, Treatment Resistant Depression (TRD), Bipolar Disorder (BD), Catatonia
- Trial name
- BIO-INM (NCT07741981)
- Testing
- Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS
The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or…
- Trial name
- SANAT (NCT00528359)
- Testing
- quetiapine or olanzapine or risperidone or aripiprazole
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Schizophrenia, Electroconvulsive Therapy
ECT in Ultra-resistant Schizophrenia
The effects of the ECT in schizophrenia ultra-resistant were studied in short times (4-6 months in most studies with follow-up).
- Trial name
- SURECT (NCT03542903)
- Testing
- Electroconvulsive therapy
- Where
- 10 sites in France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier du Rouvray
Schizophrenia
Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia
This is a randomized, placebo-controlled study to assess the efficacy and safety of ATX augmentation of CLZ as a treatment for the cognitive symptoms of schizophrenia.
- Trial name
- NCT00216281
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Indiana University